Skip to main content
. 2024 Apr 9;115(6):1834–1850. doi: 10.1111/cas.16171

FIGURE 4.

FIGURE 4

AIM2 promotion of KRAS‐driven LAC augments immune cell infiltrates, and requires hematopoietic and non‐hematopoietic cellular compartments. (A, C, E) Representative images of lung sections containing lesions from Kras G12D and Kras G12D:Aim2 −/− mice at 6 weeks post Ad‐Cre inhalation immunostained with antibodies against (A) CD3, (C) B220 and (E) F4/80. Scale bars: 100 μm. (B, D, F) Quantification of positive cells/high‐power field (HPF) in lesion‐bearing mouse lungs immunostained with antibodies against (B) CD3, (D) B220 and (F) F4/80 (n = 6/genotype). *p < 0.05, Student's t‐test. (G) Representative images of H&E‐stained lung sections from Kras G12D (G12D) or Kras G12D:Aim2 −/− (G12D:Aim2 −/−) recipient mice reconstituted with Kras G12D or Kras G12D:Aim2 −/− donor bone marrow (indicated in superscript font). Insets depict magnified areas comprising lesions in the low‐power images (open squares). Scale bars: 3 mm. (H, I) Quantification of (H) lung parenchyma area containing tumor lesions, and (I) tumor incidence, per whole mouse lung in chimeras (n = 5/group). **p < 0.01, ***p < 0.001; One‐way ANOVA.